NASA awards $5 million to artificial retina development efforts

Article

key opens lock in eye

LambdaVision and its partner SpaceTango have been selected by National Aeronautics and Space Administration (NASA) to receive a $5 million reward toward the development of the first protein-based artificial retina. Researchers hope the novel treatment will help blind patients and those with significant sight loss due to advanced retinitis pigmentosa (RP) regain sight. The artificial retina offers secondary application as well in age-related macular degeneration (AMD) andother retinal degenerative diseases, according to the company.

The protein-based, artificial retinas produced in the program imitate human photoreceptors’ light-absorbing properties. They are capable of awakening deteriorating retinas of blind and nearly blind patients, thereby regaining sight.

Related: Companies offer CE, other resources amid coronavirus pandemic

The award includes a series of flights to the International Space Station (ISS) U.S. national laboratory over a three-year period to improve on-orbit processes relating to the production of artificial retinas. LambdaVision and SpaceTango are focused on using the microgravity environment to optimize manufacturing parameters for the assembly of retinal implants.

Artificial retinas are already produced on Earth through a layer-by-layer construction process, but researchers at LambdaVision believes microgravity may reduce the amount of materials required, thereby lowering costs and accelerating manufacturing.

Once the process is legitimized and production goals are reached, it could lead the way for more space-manufactured medical products to be developed.

In a statement, Twyman Clements, co-founder and chief executive officer of SpaceTango says, “As we explore the seemingly immense ways in which microgravity can benefit the development and production of a wide range of products, our long-term collaboration with LambdaVision continues to provide us with valuable learnings that might one day help some patients regain sight and may also lead to other important production discoveries.”

More by Brooke Beery: COVID-19: Key metrics ranked by state

Recent Videos
Optometrists reflect on their residency experiences and provide advice to current residents.
EnVision Summit Co-chairs Sherrol Reynolds, OD, FAAO; Katie Rachon, OD, FAAO, Dipl ABO; Jessica Steen, OD, FAAO, Dipl ABO; and Cecelia Koetting, OD, FAAO, Dipl ABO; express excitement for the upcoming conference and why optometrists should attend.
Bonnie An Henderson, MD, the cofounder and program director of EnVision Summit
What was the biggest innovation in eye care in 2024?
In 2 weeks, the study participant's dry eye symptoms improved from 76 to 43 on a 0-100 rating scale, according to Marc-Matthias Schulze, PhD, Dipl Ing.
Eye care practitioners reported moderate to high satisfaction with lifitegrast's ability to improve signs of dry eye, according to Melissa Barnett, OD, FAAO, FSLS.
Neda Gioia, OD, CNS, FOWNS, details the positive feedback gained so far from other optometrists that have been prescribing the NutriTears supplement to their dry eye patients.
Damaris Raymondi, OD, FAAO, highlighted the importance of building patient-doctor trust to learn about these practices, which can include non-traditional treatments like chamomile or manuka honey eye drops.
Noreen Shaikh, OD, Magdalena Stec, OD, FAAO, and Brenda Bohnsack, MD, PhD, emphasize that collaboration and communication are key to proper diagnosis and treatment.
Cecilia Koetting, OD, FAAO, DipABO, cited data from a recent student that found that presbyopia treatment with 0.4% pilocarpine led to up to 86% of patients achieving 20/40 or better.
© 2024 MJH Life Sciences

All rights reserved.